Akademska digitalna zbirka SLovenije - logo

Rezultati iskanja

Osnovno iskanje    Izbirno iskanje   
Iskalna
zahteva
Knjižnica

Trenutno NISTE avtorizirani za dostop do e-virov konzorcija SI. Za polni dostop se PRIJAVITE.

2 3 4 5 6
zadetkov: 6.703
31.
  • Dissecting the clinicopatho... Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer
    Ricciuti, B.; Alessi, J.V.; Elkrief, A. ... Annals of oncology, 10/2022, Letnik: 33, Številka: 10
    Journal Article
    Recenzirano
    Odprti dostop

    Allele-specific KRAS inhibitors are an emerging class of cancer therapies. KRAS-mutant (KRASMUT) non-small-cell lung cancers (NSCLCs) exhibit heterogeneous outcomes, driven by differences in ...
Celotno besedilo
Dostopno za: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
32.
  • Reverse vaccinology and imm... Reverse vaccinology and immunoinformatics approaches to design multi-epitope based vaccine against oncogenic KRAS
    Ramalingam, Prasanna Srinivasan; Arumugam, Sivakumar Medical oncology (Northwood, London, England), 08/2023, Letnik: 40, Številka: 10
    Journal Article
    Recenzirano
    Odprti dostop

    Mutant KRAS-induced tumorigenesis is highly involved in the progression of pancreatic, lung, and breast cancer. Comparatively, KRAS G12D and KRAS G12C are the most frequent mutations that promote ...
Celotno besedilo
Dostopno za: EMUNI, FIS, FZAB, GEOZS, GIS, IJS, IMTLJ, KILJ, KISLJ, MFDPS, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, SBMB, SBNM, UKNU, UL, UM, UPUK, VKSCE, ZAGLJ
33.
  • Targeting the MAPK Pathway ... Targeting the MAPK Pathway in KRAS-Driven Tumors
    Drosten, Matthias; Barbacid, Mariano Cancer cell, 04/2020, Letnik: 37, Številka: 4
    Journal Article
    Recenzirano
    Odprti dostop

    KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been approved to treat these tumors. Despite the recent development of drugs that block KRASG12C, the majority of ...
Celotno besedilo
Dostopno za: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP

PDF
34.
  • Exosomal lncRNA PCAT-1 prom... Exosomal lncRNA PCAT-1 promotes Kras-associated chemoresistance via immunosuppressive miR-182/miR-217 signaling and p27/CDK6 regulation
    Domvri, Kalliopi; Petanidis, Savvas; Anestakis, Doxakis ... Oncotarget, 07/2020, Letnik: 11, Številka: 29
    Journal Article
    Odprti dostop

    Immunosuppressive chemoresistance is a major burden in lung cancer. Recent data reveal that long noncoding RNAs (lncRNAs) present in the lung tumor microenvironment are implicated in ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK

PDF
35.
  • KRAS Secondary Mutations Th... KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
    Koga, Takamasa; Suda, Kenichi; Fujino, Toshio ... Journal of thoracic oncology, 08/2021, Letnik: 16, Številka: 8
    Journal Article
    Recenzirano
    Odprti dostop

    KRAS mutations have been recognized as undruggable for many years. Recently, novel KRAS G12C inhibitors, such as sotorasib and adagrasib, are being developed in clinical trials and have revealed ...
Celotno besedilo
Dostopno za: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP

PDF
36.
  • Revealing the mechanism of ... Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMR
    Sharma, Alok K.; Pei, Jun; Yang, Yue ... The Journal of biological chemistry, 02/2024, Letnik: 300, Številka: 2
    Journal Article
    Recenzirano
    Odprti dostop

    Individual oncogenic KRAS mutants confer distinct differences in biochemical properties and signaling for reasons that are not well understood. KRAS activity is closely coupled to protein dynamics ...
Celotno besedilo
Dostopno za: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
37.
  • Revealing the mechanism of ... Revealing the mechanism of action of a first-in-class covalent inhibitor of $\mathrm{KRASG12C}$ $\mathrm{(ON)}$ and other functional properties of oncogenic $\text{KRAS}$ by 31P $\mathrm{NMR}
    Sharma, Alok K.; Pei, Jun; Yang, Yue ... The Journal of biological chemistry, 01/2024, Letnik: 300, Številka: 2
    Journal Article
    Recenzirano
    Odprti dostop

    Individual oncogenic KRAS mutants confer distinct differences in biochemical properties and signaling for reasons that are not well understood. KRAS activity is closely coupled to protein dynamics ...
Celotno besedilo
Dostopno za: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
38.
  • Prognostic value of KRAS G1... Prognostic value of KRAS G12C mutation in lung adenocarcinoma stratified by stages and radiological features
    Cao, Hang; Ma, Zelin; Li, Yuan ... The Journal of thoracic and cardiovascular surgery, 12/2023, Letnik: 166, Številka: 6
    Journal Article
    Recenzirano

    The role of KRAS G12C is of particular interest given the promising clinical activity of KRAS G12C-specific inhibitors. This study comprehensively investigated the clinicopathological characteristics ...
Celotno besedilo
Dostopno za: NUK, UL
39.
  • Assessment of KRASG12C inhi... Assessment of KRASG12C inhibitors for colorectal cancer
    Piazza, Gary A.; Chandrasekaran, Preethi; Maxuitenko, Yulia Y. ... Frontiers in oncology, 06/2024, Letnik: 14
    Journal Article
    Recenzirano
    Odprti dostop

    Colorectal cancer (CRC) is a highly prevalent and lethal cancer worldwide. Approximately 45% of CRC patients harbor a gain-in-function mutation in KRAS. KRAS is the most frequently mutated oncogene ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK
40.
  • Nanotechnology-assisted int... Nanotechnology-assisted intracellular delivery of antibody as a precision therapy approach for KRAS-driven tumors
    López-Estévez, Ana M.; Sanjurjo, Lucía; Turrero, Ángela ... Journal of controlled release, September 2024, Letnik: 373
    Journal Article
    Recenzirano
    Odprti dostop

    The Kirsten Rat Sarcoma Virus (KRAS) oncoprotein, one of the most prevalent mutations in cancer, has been deemed undruggable for decades. The hypothesis of this work was that delivering anti-KRAS ...
Celotno besedilo
Dostopno za: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
2 3 4 5 6
zadetkov: 6.703

Nalaganje filtrov